Goldman Sachs Suggests Buying Calendar Spreads on United Therapeutics Corporation (UTHR)

Goldman Sachs is out with a research note this morning, where it suggests that traders buy calendar spreads on Aruba Networks UTHR ahead of upcoming positive Phase 3 data.

Goldman Sachs Biotechnology analyst, Terence Flynn, rates UTHR shares Buy and sees 19% upside to his 12-month price target of $82. He rates UTHR a M&A probability of 1 (strong, 30% - 50% probability in one year) once results from Phase 3 data on their upcoming Pulmonary Arterial Hypertension (PAH) are released this year.

Goldman suggests buying the August $75.00 call and selling the January 2012 $90.00 call for a net debit of $1.45

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases.